Skip to main content
OpenTrials
Completed

NCT Number: NCT06626568

Comparison of Ultrasound-Guided Subacromial vs. Systemic Steroid Injections for Frozen Shoulder: a Multicenter Pilot Study

The goal of this multicenter pilot study is to validate the effectiveness of extending the injection interval between betamethasone doses from one to two weeks for treating frozen shoulder (adhesive capsulitis) in adults aged 18 to 75. This study also aims to screen potential study centers and gather data to refine the sample size calculation for a larger, future trial. The main questions it aims to answer are:

* Does extending the interval between injections maintain effectiveness in improving shoulder function and reducing pain for frozen shoulder? * Which centers in this pilot study are qualified for a larger, future trial? * What is the appropriate sample size for conducting a multicenter RCT study with the same research design at the selected centers?

Participants will:

* Receive 3 injections over 4 weeks and will be followed up for another 8 weeks * Complete shoulder function assessments * Perform home rehabilitation exercises

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Guangde County People's Hospital, Xuancheng, Anhui, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • History of ≤9 months, clinically diagnosed with primary frozen shoulder (including frozen shoulder associated with diabetes).
  • Aged between 18 and 75 years old
  • Pain NRS score ≥4
  • Measured passive range of motion of the affected shoulder in at least two of the three directions (forward flexion, external rotation with arm at the side, and internal rotation with arm at the side) is reduced by 25% or more compared to the contralateral normal shoulder.
  • Exclusion of osteoarthritis, dislocation, and other shoulder abnormalities through X-ray and MRI of the affected shoulder.

Exclusion criteria

  • Secondary frozen shoulder caused by thyroid disease, cardiovascular disease, cancer, stroke, radiotherapy, neurosurgery, or breast surgery (excluding diabetes); secondary frozen shoulder caused by major shoulder trauma requiring medical care (e.g., fractures, dislocations, rotator cuff tears).
  • Full-thickness rotator cuff tear in the affected shoulder confirmed by MRI (excluding rotator cuff tendinopathy and partial-thickness rotator cuff tear in patients with frozen shoulder without a history of major shoulder trauma).
  • Patients unable to undergo MRI due to financial reasons, claustrophobia, pacemaker, or other metallic implants in the body.
  • Local infection in the affected shoulder or other contraindications to shoulder injections.
  • Patients with contraindications to steroid therapy (e.g., poorly controlled blood sugar in diabetes).
  • Patients with frozen shoulder who have already undergone shoulder injections, manipulation under anesthesia, arthroscopic capsular release, or open surgery for capsular release.
  • Received any form of steroid treatment within the past 3 months.
  • History of glucocorticoid use for more than 3 months.
  • Bilateral frozen shoulder or a history of frozen shoulder in the contralateral shoulder.
  • Pregnant or breastfeeding women.
  • Patients lacking the cognitive ability to comply with the study protocol.
  • Patients not residing in the area where the study is being conducted.
  • Patients with compensation claims or legal disputes related to workplace injury or car accidents.

Treatment and study plan

Compound betamethasone Injection(Gluteal muscle injection)

Drug

gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4

Compound betamethasone Injection(Subacromial Ultrasound Guided injection)

Drug

ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.

Normal Saline as Placebo (ultrasound-guided subacromial injection)

Other

ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.

Normal Saline as Placebo (gluteal muscle inection)

Other

gluteal injection of 5 ml normal saline at week 0,2,4.

Home exercise

Behavioral

The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.

Primary outcomes

  1. Shoulder Pain and Disability Index (SPADI)

    Time frame: Baseline and 12 weeks

    The SPADI score ranges from 0 to 100. A score of 0 indicates no pain or disability, while a score of 100 reflects the worst possible pain and maximum functional disability in the shoulder.

    Data entry will be performed by blinded research staff. They will present the paper CRF sample form to the participants and ask questions one by one, directly entering the responses of participants into the corresponding electronic CRF form in the EDC system using handheld electronic devices (such as smartphones, tablets, or laptops).

Secondary outcomes

  1. progression rate of rotator cuff tears

    Time frame: From enrollment to the end of follow-up at 12 weeks

    Third-party experts will conduct blinded readings of shoulder MRI scans, classifying rotator cuff status into three grades: Grade I (intact), Grade II (partial tear), and Grade III (complete tear). Patients classified as Grade III at week 0 will be excluded from the study, as baseline grading (determined by each research center) assesses eligibility per exclusion criterion 2. The lead center provided MRI reading training to all centers, using T2-weighted images with a pure white fluid signal occupying full or partial thickness of the rotator cuff across at least two consecutive MRI slices as the diagnostic criterion for full- or partial-thickness tears. Patients with Grade I or II tears at week 0 will receive study treatment and be followed up at week 12. Tear progression is defined as an increase of at least one grade between weeks 0 and 12, assessed by blinded experts. The progression rate is the number of subjects with progression divided by the total number in each group.

  2. short version of Disabilities of the Arm, Shoulder, and Hand Questionnaire (QuickDASH)

    Time frame: Baseline and 12 weeks

    The QuickDASH score ranges from 0 to 100. A score of 0 means no disability, and a score of 100 signifies the highest level of disability related to arm, shoulder, and hand function.

    Data entry will be performed by blinded research staff. They will present the paper CRF sample form to the participants and ask questions one by one, directly entering the responses of participants into the corresponding electronic CRF form in the EDC system using handheld electronic devices (such as smartphones, tablets, or laptops).

  3. Numerical Rating Scale (NRS)

    Time frame: Baseline and 12 weeks

    The NRS score ranges from 0 to 10. A score of 0 indicates no pain, while a score of 10 reflects the worst possible pain.

    Data entry will be performed by blinded research staff. They will present the paper CRF sample form to the participants and ask questions one by one, directly entering the responses of participants into the corresponding electronic CRF form in the EDC system using handheld electronic devices (such as smartphones, tablets, or laptops).

  4. five-level EuroQol five-dimensional questionnaire (EQ-5D-5L)

    Time frame: Baseline and 12 weeks

    The EQ-5D-5L provides an overall health utility score ranging from -0.281 to 1, where 1 represents perfect health, zero represents a state equivalent to death, and negative values indicate health states worse than death.

    It also reports on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on five levels from no problems to extreme problems.

    Data entry will be performed by blinded research staff. They will present the paper CRF sample form to the participants and ask questions one by one, directly entering the responses of participants into the corresponding electronic CRF form in the EDC system using handheld electronic devices (such as smartphones, tablets, or laptops).

  5. passive range of motion of shoulder

    Time frame: Baseline and 12 weeks

    The passive range of motion for shoulder flexion, abduction, internal rotation (at the side), and external rotation (at the side) on the affected side will be measured using a goniometer by trained researchers following a pre-established standard operating procedure.

  6. Direct Medical Cost

    Time frame: Baseline

    The costs of healthcare resources used for the diagnosis and treatment of frozen shoulder of the participant, including medication fees, medical expenses, testing fees, nursing fees and hospitalization costs. The questionnaire surveys the cost by the participant since the onset of frozen shoulder.

  7. Direct Medical Cost

    Time frame: Baseline and week2

    The costs of healthcare resources used for the diagnosis and treatment of frozen shoulder of the participant, including medication fees, medical expenses, testing fees, nursing fees and hospitalization costs. The questionnaire surveys the cost by the participant since the last outpatient research follow-up.

  8. Direct Medical Cost

    Time frame: Week2 and week4

    The costs of healthcare resources used for the diagnosis and treatment of frozen shoulder of the participant, including medication fees, medical expenses, testing fees, nursing fees and hospitalization costs. The questionnaire surveys the cost by the participant since the last outpatient research follow-up.

  9. Direct Medical Cost

    Time frame: Week4 and week8

    The costs of healthcare resources used for the diagnosis and treatment of frozen shoulder of the participant, including medication fees, medical expenses, testing fees, nursing fees and hospitalization costs. The questionnaire surveys the cost by the participant since the last outpatient research follow-up.

  10. Direct Medical Cost

    Time frame: Week8 and week12

    The costs of healthcare resources used for the diagnosis and treatment of frozen shoulder of the participant, including medication fees, medical expenses, testing fees, nursing fees and hospitalization costs. The questionnaire surveys the cost by the participant since the last outpatient research follow-up.

  11. work absenteeism

    Time frame: Week 0

    The questionnaire surveys the number of workdays missed since the onset of frozen shoulder is collected at baseline.

  12. work absenteeism

    Time frame: Week 0 and Week 2

    The questionnaire surveys the number of workdays missed by the subject since the last outpatient research follow-up.

  13. work absenteeism

    Time frame: Week 2 and Week 4

    The questionnaire surveys the number of workdays missed by the subject since the last outpatient research follow-up.

  14. work absenteeism

    Time frame: Week 4 and Week 8

    The questionnaire surveys the number of workdays missed by the subject since the last outpatient research follow-up.

  15. work absenteeism

    Time frame: Week 8 and Week 12

    The questionnaire surveys the number of workdays missed by the subject since the last outpatient research follow-up.

  16. Unplanned concomitant use of analgesics

    Time frame: Week 2

    This questionnaire surveys the usage of unplanned concomitant analgesic medications by the subject since the last outpatient research follow-up.

  17. Unplanned concomitant use of analgesics

    Time frame: Week 4

    This questionnaire surveys the usage of unplanned concomitant analgesic medications by the subject since the last outpatient research follow-up.

  18. Unplanned concomitant use of analgesics

    Time frame: Week 8

    This questionnaire surveys the usage of unplanned concomitant analgesic medications by the subject since the last outpatient research follow-up.

  19. Unplanned concomitant use of analgesics

    Time frame: Week 12

    This questionnaire surveys the usage of unplanned concomitant analgesic medications by the subject since the last outpatient research follow-up.

  20. Glycated Hemoglobin (HbA1c)

    Time frame: week 0 and week 12

    Depending on the specific assay methods used by the laboratory departments of different study centers, HbA1c will be measured by high-Performance Liquid Chromatography (HPLC), Immunoturbidimetric Method, Enzymatic Method, Affinity Chromatography, Electrophoresis, Capillary Electrophoresis or Ion-Exchange Chromatography.

  21. glycated albumin

    Time frame: week 0 and week 4

    Depending on the specific assay methods used by the laboratory departments of different study centers, glycated albumin will be measured by Enzymatic Method, Immunoturbidimetric Method, High-Performance Liquid Chromatography (HPLC), Affinity Chromatography, or Immunoelectrophoresis.

Other outcomes

  1. incidence of serious adverse events (SAE)

    Time frame: From enrollment to the end of follow-up at 12 weeks

    The incidence of serious adverse events (SAE) at 12 weeks

  2. incidence of adverse events (AE)

    Time frame: From enrollment to the end of follow-up at 12 weeks

    The incidence of adverse events (AE) at 12 weeks

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Comparison Between Ultrasound Guided Subacromial and Systemic Injection of Steroid for Frozen Shoulder: a Double Blind Multicenter Pilot Study for Randomized Control Trial

Acronym: CUSIS-FS-Pilot

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 4, 2024
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.